Glycoprotein 41 (gp41) - Pipeline Review, H1 2018
Glycoprotein 41 (gp41) - Pipeline Review, H1 2018
Summary
According to the recently published report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.
The report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 6 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in the Report
Amunix Operating Inc
Frontier Biotechnologies Inc
InnaVirVax SA
Longevity Biotech Inc
Mymetics Corp
Navigen Inc
Osel Inc
Pharis Biotec GmbH
Sanofi Pasteur SA
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) - Overview
Glycoprotein 41 (gp41) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
Amunix Operating Inc
Frontier Biotechnologies Inc
InnaVirVax SA
Longevity Biotech Inc
Mymetics Corp
Navigen Inc
Osel Inc
Pharis Biotec GmbH
Sanofi Pasteur SA
Glycoprotein 41 (gp41) - Drug Profiles
CPT-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enfuvirtide-XTEN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FB-006M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STOP-3S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-3S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCP-2438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) - Dormant Products
Glycoprotein 41 (gp41) - Discontinued Products
Glycoprotein 41 (gp41) - Product Development Milestones
Featured News & Press Releases
Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
Nov 28, 2016: First new HIV vaccine efficacy study in seven years has begun
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa
Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine
Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amunix Operating Inc, H1 2018
Pipeline by Frontier Biotechnologies Inc, H1 2018
Pipeline by InnaVirVax SA, H1 2018
Pipeline by Longevity Biotech Inc, H1 2018
Pipeline by Mymetics Corp, H1 2018
Pipeline by Navigen Inc, H1 2018
Pipeline by Osel Inc, H1 2018
Pipeline by Pharis Biotec GmbH, H1 2018
Pipeline by Sanofi Pasteur SA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Research Methodology
The research study released with title "Glycoprotein 41 (gp41) - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Glycoprotein 41. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Glycoprotein 41 who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Glycoprotein 41 as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Glycoprotein 41 study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Glycoprotein 41 (gp41) - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
